CONTINEUM THERAPEUTICS INC-A (CTNM)

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

CTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Contineum Therapeutics (NASDAQ:CTNM) just reported results for the second quart...

CTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024

CTNM stock results show that Contineum Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

BTIG Just MASSIVELY Raised Its Price Target on MicroStrategy (MSTR) Stock

MicroStrategy stock is up on Friday after shares of MSTR got an increased price target from BTIG analysts and a buy rating.

CTNM Stock: 7 Things to Know as Contineum Therapeutics Starts Trading Today

Contineum Therapeutics stock is getting ready to start trading on Friday with plans for a $110 million IPO for shares of CTNM.

Contineum Therapeutics Announces Pricing of Initial Public Offering

Contineum Therapeutics Announces Pricing of Initial Public Offering

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering...